Masimo Co. (NASDAQ:MASI) is Ace Management Global Ltd.’s Largest Position

Ace Management Global Ltd. lessened its holdings in Masimo Co. (NASDAQ:MASI) by 95.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 47,694 shares of the medical equipment provider’s stock after selling 917,810 shares during the quarter. Masimo comprises approximately 100.0% of Ace Management Global Ltd.’s investment portfolio, making the stock its largest holding. Ace Management Global Ltd.’s holdings in Masimo were worth $7,884,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MASI. ING Groep NV lifted its position in shares of Masimo by 143.3% during the 3rd quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock worth $32,119,000 after purchasing an additional 141,900 shares during the last quarter. Westfield Capital Management Co. LP lifted its position in shares of Masimo by 23.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after purchasing an additional 262,370 shares during the last quarter. National Bank of Canada FI lifted its position in shares of Masimo by 195.6% during the 3rd quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider’s stock worth $17,666,000 after purchasing an additional 87,675 shares during the last quarter. Lecap Asset Management Ltd. purchased a new stake in shares of Masimo during the 4th quarter worth $1,607,000. Finally, Nisa Investment Advisors LLC lifted its position in shares of Masimo by 16,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider’s stock worth $835,000 after purchasing an additional 5,022 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Trading Up 1.5 %

NASDAQ MASI opened at $186.19 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm has a market cap of $10.04 billion, a PE ratio of 128.41 and a beta of 1.02. Masimo Co. has a one year low of $101.61 and a one year high of $194.88. The firm’s fifty day moving average is $174.79 and its two-hundred day moving average is $155.27.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Analysts expect that Masimo Co. will post 4.1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on MASI. Wells Fargo & Company lifted their price target on shares of Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Piper Sandler lifted their price target on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Raymond James lifted their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.